Omexta Mechanism of Action

Pharmacology: Pharmacodynamics: Olmesartan medoxomil is a selective angiotensin II receptor (type AT1) antagonist. It is expected to block all actions of angiotensin II mediated by the AT1 receptor, regardless of the source or route of synthesis of angiotensin II.
Angiotensin II is the primary vasoactive hormone of the renin-angiotensin-aldosterone system and plays a significant role in the pathophysiology of hypertension. Olmesartan medoxomil blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II and interacts reversibly at the AT1 and AT2 receptors of many tissues. Olmesartan medoxomil does not affect the response to bradykinin.
Pharmacokinetics: Olmesartan medoxomil is an ester prodrug that is hydrolyzed during absorption from the gastrointestinal tract to the active form Olmesartan. No further metabolism occurs. The absolute bioavailability is about 26%. Peak plasma concentrations of Olmesartan occur about 1 to 2 hours after oral doses. Olmesartan is at least 99% bound to plasma proteins. It is excreted in the urine and the bile as Olmesartan; about 35 to 50% of the absorbed dose is excreted in the urine and the remainder in feces via the bile. The terminal elimination half-life is 13 hours.